Premium Nahrungsergänzungsmittel | artgerecht

Cholestasis Therapy – Treatment and Medications

Cholestasis therapy refers to all measures used to treat impaired bile flow. The goal is to restore normal bile drainage and prevent liver damage.

Regular tips about health Regular tips about health

Things worth knowing about "Cholestasis Therapy"

Cholestasis therapy refers to all measures used to treat impaired bile flow. The goal is to restore normal bile drainage and prevent liver damage.

What is Cholestasis?

Cholestasis is a condition in which the flow of bile from the liver is reduced or blocked. This leads to a buildup of bile acids, bilirubin, and other bile components in the blood and liver tissue. Cholestasis can originate within the liver (intrahepatic cholestasis) or outside the liver (extrahepatic cholestasis), and treatment depends heavily on the underlying cause.

Causes of Cholestasis

The causes of cholestasis are diverse and directly influence the choice of treatment:

Intrahepatic causes: Liver diseases such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), viral hepatitis, drug-induced liver injury, and intrahepatic cholestasis of pregnancy
Extrahepatic causes: Gallstones in the bile ducts, tumors of the bile ducts or pancreas, and biliary strictures

Goals of Cholestasis Therapy

Treatment of cholestasis aims to address the underlying cause, relieve symptoms such as pruritus (itching) and jaundice, and prevent long-term complications including liver fibrosis and liver failure.

Treatment Options

Pharmacological Therapy

For many forms of cholestasis, drug treatment is the first-line approach:

Ursodeoxycholic acid (UDCA): The most widely used medication for cholestatic liver diseases, particularly PBC. UDCA promotes bile flow, protects liver cells, and reduces inflammation.
Obeticholic acid: A newer agent used when UDCA response is inadequate in PBC. It acts as a farnesoid X receptor (FXR) agonist, regulating bile acid metabolism.
Rifampicin: Used to treat cholestasis-associated pruritus by inducing hepatic detoxification enzymes.
Cholestyramine: A bile acid sequestrant that binds bile acids in the intestine, reducing their reabsorption and alleviating itching.
Naltrexone and sertraline: These agents are used as add-on treatments for refractory pruritus.

Endoscopic and Interventional Therapy

When mechanical obstructions such as gallstones or biliary strictures are present, minimally invasive procedures are used:

ERCP (Endoscopic Retrograde Cholangiopancreatography): Allows removal of gallstones, dilation of strictures, and placement of stents to restore bile flow.
Percutaneous Transhepatic Cholangiodrainage (PTCD): A drainage catheter is placed through the skin into the bile ducts when endoscopic access is not feasible.

Surgical Therapy

Surgery may be required when endoscopic approaches are insufficient, for example to remove tumors, create biliodigestive anastomoses, or in end-stage liver disease, to perform a liver transplantation.

Treatment of Cholestasis in Pregnancy

Intrahepatic cholestasis of pregnancy (ICP) requires particularly careful management due to associated risks for the unborn child. UDCA is the first-line treatment. Close monitoring and, if necessary, early delivery are recommended.

Nutrition and Supportive Measures

In addition to medical treatment, the following supportive measures are recommended:

Low-fat diet to reduce the burden on bile secretion
Supplementation of fat-soluble vitamins (A, D, E, K), as their absorption is impaired in cholestasis
Avoidance of alcohol and potentially hepatotoxic medications
Regular medical follow-up and monitoring

Prognosis

The prognosis of cholestasis depends greatly on the underlying cause and the timeliness of diagnosis. Early and consistent therapy can significantly improve the disease course and help prevent serious complications such as liver cirrhosis.

References

European Association for the Study of the Liver (EASL): EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. Journal of Hepatology, 2017.
Lindor KD et al.: Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology, 2019.
Williamson C et al.: Intrahepatic cholestasis of pregnancy. The Lancet, 2023.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category